Hostname: page-component-6766d58669-kn6lq Total loading time: 0 Render date: 2026-05-19T22:26:24.042Z Has data issue: false hasContentIssue false
  • English
  • Français

Mood Stabilizers in the Treatment of Substance Use Disorders

Published online by Cambridge University Press:  07 November 2014

Icro Maremmani ,
Matteo Pacini ,
Francesco Lamanna ,
Pier Paolo Pani ,
Giulio Perugi ,
Joseph Deltito ,
Ihsan M. Salloum  and
Hagop Akiskal
Get access Rights & Permissions [Opens in a new window]

Abstract

Individuals suffering from drug addiction may also manifest features of bipolar spectrum disorders. Hyperthymic and cyclothymic temperaments may render individuals vulnerable to later development of substance abuse. Bipolar disorders themselves may be altered or precipitated by substance use, most notably by stimulants (amphetamines), alcohol, and cannabinoids.The clinical usefulness of mood stabilizers, particularly antiepileptics, has been established as safe and effective in substance abusers with and without comorbid mood disorders. Most studies on this issue have been of short duration and focused on the resolution of a currently manifest period of illness. Few studies have been conducted on the usefulness of these drugs on the long-term longitudinal course of these diseases, such as frequently encountered recurrent relapses into states of agitation, impulsivity, and/or dissatisfaction. As opposed to the clinical experience with traditional antidepressants and neuroleptics, antiepileptics do not induce counter-polar states (depressed patients abruptly turning manic or hypomanic; nor patients currently hypomanic or manic turning abruptly depressed). Many clinicians consider antiepileptic mood stabilizers to be the preferred category of medications for the treatment of such patients. Valproate appears to be a potentially fruitful medication to study in these dual diagnosis patients due to preliminary evidence demonstrating its anticraving efficacy.

Information

Type
Review Article
Information
CNS Spectrums , Volume 15 , Issue 2 , February 2010 , pp. 95 - 109
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

REFERENCES

1.Regier, DA, Farmer, ME, Rae, DS, et al.Comorbidity of mental disorders with alchool and other drug abuse. JAMA. 1990;19:2511–2518.CrossRefGoogle Scholar
2.Kessler, RC, McGonagle, KA, Zhao, S, et al.Lifetime and 12-month prevalence of DSM-IIIR psychiatric disorders in the United States:results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8–19.CrossRefGoogle Scholar
3.Kessler, RC, Nelson, CB, McGonagle, KA, Edlund, MJ, Frank, RG, Leaf, PJ. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry. 1996;66:17–31.CrossRefGoogle ScholarPubMed
4.Grant, BRHarford, TC. Comorbidity between DSM-IV alcohol use disorders and major depression: results of a national survey. Drug Alcohol Depend. 1995;39:197–206.CrossRefGoogle ScholarPubMed
5.Merikangas, KR, Mehta, RL, Molnar, BE, et al.Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Addict Behav. 1998;23:893–907.CrossRefGoogle Scholar
6.Grant, BF, Stinson, FS, Dawson, DA, et al.Prevalence and co-occurrence of substance use disorders and Independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61:807–816.CrossRefGoogle ScholarPubMed
7.Swendsen, JD, Merikangas, KR. The comorbidity of depression and substance use disorders. Clin Psychol Rev. 2000;20:173–189.CrossRefGoogle ScholarPubMed
8.Freed, EX. Alcohol abuse by manic patients. Psychol Rep. 1969;25:280.CrossRefGoogle ScholarPubMed
9.Dunner, DL. Hensel, BM, Fieve, RR. Bipolar illness: factors in drinking behavior. Am J Psychiatry. 1979;136:583–585.CrossRefGoogle ScholarPubMed
10.Hensel, B, Dunner, DL, Fieve, RR. The relationship of family history of alcoholism to primary affective disorder. J Affect Disord. 1979;1:105–113.CrossRefGoogle ScholarPubMed
11.Estroff, TW, Dackls, CA, Gold, MS, Pottash, ALC. Drug abuse and bipolar disorders. Int J Psychiatry Med. 1985;15:37–40.CrossRefGoogle ScholarPubMed
12.Bernardt, MW, Murray, RM. Psychiatric disorder, drinking and alcoholism: what are the links? Br J Psychiatry. 1986;148:393–400.CrossRefGoogle Scholar
13.Miller, FT, Busch, F, Tanenbaum, JH. Drug abuse in schizophrenia and bipolar disorders. Am J Drug Alcohol Abuse. 1989;15:291–295.CrossRefGoogle Scholar
14.Weiss, RD, Greenfield, SFNajavlts, LM, et al.Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry. 1998;59:172–174.CrossRefGoogle ScholarPubMed
15.Goldberg, JF, Garno, JL, Leon, AC, Kocsis, JH, Portera, L. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry. 1999;60:733–740.CrossRefGoogle ScholarPubMed
16.Helzer, JE, Pryzbeck, TR. The co-occurrence of alcoholism with other psychiatric disorders in the general population and its Impact on treatment. J Stud Alcohol. 1988;49:219–224.CrossRefGoogle ScholarPubMed
17.Mayfleld, DG, Coleman, LL. Alcohol use and affective disorder. Dis Nerv Syst. 1968;29:467–474.Google Scholar
18.Reich, LH, Davies, RK, Himmelhoch, JM. Excessive alcohol use in manic-depressive illness. Am J Psychiatry. 1974;131:83–86.CrossRefGoogle ScholarPubMed
19.Winokur, G, Coryell, W, Endlcott, J, Keller, M, Akiskal, HS, Solomon, D. Familial alcoholism in manic-depressive (bipolar) disease. Am J Med Genet. 1996;67:197–201.3.0.CO;2-E>CrossRefGoogle ScholarPubMed
20.Mirin, SM, Weiss, R, Michael, J, Griffin, M. Psychopathology in substance abusers: Diagnosis and treatment. Am J Drug Alcohol Abuse. 1988;14:139–157.CrossRefGoogle ScholarPubMed
21.Bisaga, A, Aharonovich, E, Garawi, Fet al.A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend. 2006;81:267–274.CrossRefGoogle ScholarPubMed
22.Rounsaville, BJ, Weissman, MM, Rosenberger, PH, Wilbur, CH, Kleber, HD. Detecting depressive disorders in drug abusers: a comparison of screening Instruments. J Affect Disord. 1979;1:255–267.CrossRefGoogle ScholarPubMed
23.Maremmani, I, Pacini, M, Pani, PRPerugi, G, Deltito, J, Akiskal, H. The Mental Status of 1090 Heroin Addicts at Entry into Treatment: Should Depression Be Considered a “Dual Diagnosis?” Ann Gen Psychiatry. 2007;6:31.CrossRefGoogle ScholarPubMed
24.Sherwood Brown, E, Suppes, T, Adinoff, B, Ryan Thomas, N. Drug abuse and bipolar disorder: comorbidity or misdiagnosis? J Affect Disord. 2001;65:105–115.CrossRefGoogle ScholarPubMed
25.Welch, SS, Linehan, MM. High-risk situations associated with parasulcide and drug use in borderline personality disorder. J Personal Disord. 2002;16:561–569.CrossRefGoogle ScholarPubMed
26.Perugi, G, Frare, F.Madaro, D, Maremmani, I, Akiskal, HS. Alcohol abuse in social phobic patients: Is there a bipolar connection? J Affect Disord. 2002;68:33–39.CrossRefGoogle Scholar
27.Maremmani, I, Perugi, G, Pacini, M, Akiskal, H. Toward a Unitary Perspective on the Bipolar Spectrum and Substance Abuse: Opiate Addiction as a Paradigm. J Affect Disord. 2006;93:1–12.CrossRefGoogle Scholar
28.Goldberg, JF, Whiteside, JE. The association between substance abuse and antide-pressant-lnduced mania in bipolar disorder: a preliminary study. J Clin Psychiatry. 2002;63:791–795.CrossRefGoogle ScholarPubMed
29.Bonson, KR, Murphy, DL. Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res. 1996;73:229–233.CrossRefGoogle ScholarPubMed
30.Tancer, M, Johanson, CE. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacologyl (Berl). 2007;189:565–573.CrossRefGoogle ScholarPubMed
31.van Harten, PN, van Trier, JC, Horwitz, EH, Matroos, GE, Hoek, HW. Cocaine as a risk factor for neuroleptic-induced acute dystonia. J Clin Psychiatry. 1998;59:128–130.CrossRefGoogle ScholarPubMed
32.Johnson, BA, Rosenthal, N, Capece, JA, et al.Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298:1691–1692.CrossRefGoogle ScholarPubMed
33.Winther, LC, Saleem, R, McCance-Katz, EF, et al.Effects of lamotrlglne on behavioral and cardiovascular responses to cocaine in human subjects. Am J Drug Alcohol Abuse. 2000;26:47–59.CrossRefGoogle ScholarPubMed
34.Hirschowitz, J, Hitzemann, R, Kovasznay, B, et al.Lithium antagonism of ethanol-induced intoxication: relationship to Intracellular lithium levels. Psychiatry Res. 1989;29:55–63.CrossRefGoogle ScholarPubMed
35.Judd, LL, Hubbard, RB, Huey, LY, Attewell, PA, Janowsky, DS, Takahashi, Kl. Lithium carbonate and ethanol Induced “highs” in normal subjects. Arch Gen Psychiatry. 1977;34:463–467.CrossRefGoogle Scholar
36.Rush, CR, Pazzaglia, PJ. Pretreatment with isradlplne, a calcium-channel blocker, does not attenuate the acute behavioral effects of ethanol in humans. Alcohol Clin Exp Res. 1998;22:539–547.CrossRefGoogle Scholar
37.Zacny, JPYajnlk, S. Effects of calcium channel inhibitors on ethanol effects and pharmacokinetics in healthy volunteers. Alcohol. 1993;10:505–509.CrossRefGoogle ScholarPubMed
38.Leweke, FM, Emrich, HM. Carbamazepine as an adjunct in the treatment of schizophrenia-like psychosis related to cannabis abuse. Int Clin Psychopharmacol. 1999;14:37–39.CrossRefGoogle ScholarPubMed
39.Haney, M, Hart, CL, Vosburg, SK, et al.Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology. 2004;29:158–170.CrossRefGoogle ScholarPubMed
40.Ballard, CG, Mohan, RN, Handy, S. Carbamazeplne in alcohol withdrawal. Br J Psychiatry. 1991;158:133.CrossRefGoogle ScholarPubMed
41.Bjorkqvlst, SE, Isohanni, M, Makela, R, Malinen, L. Ambulant treatment of alcohol withdrawal symptoms with carbamazeplne: a formal multicentre doubl-blind comparison with placebo. Acta Psychiatr Scand. 1976;53:333–342.CrossRefGoogle Scholar
42.Chu, NS. Carbamazepine: prevention of alcohol withdrawal seizures. Neurology. 1979;29:1397–1401.CrossRefGoogle ScholarPubMed
43.Butler, D, Messiha, FS. Alcohol withdrawal and carbamazepine. Alcohol. 1986;3:113–129.CrossRefGoogle ScholarPubMed
44.Lemke, MR. (Differential diagnostic-therapeutic use of Carbamazepine in alcohol withdrawal syndrome]. Nervenarzt. 1995;66:77–79.Google ScholarPubMed
45. See S. Carbamazepine effective for alcohol withdrawal. J Fam Pract. 2002;51:778.Google Scholar
46.Agricola, R, Mazzarino, M, Urani, R, Gallo, V, Grossi, E. Treatment of acute alcohol withdrawal syndrome with carbamazepine: a double-blind comparison with tiapride. J Int Med Res. 1982;10:160–165.CrossRefGoogle ScholarPubMed
47.Hillborn, M, Tokola, R, Kuusela, V, et al.Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid. Alcohol. 1989;6:223–226.CrossRefGoogle Scholar
48.Flygenring, J, Hansen, J, Holst, B, Petersen, E, Sorensen, A. Treatment of alcohol withdrawal symptoms in hospitalized patients. A randomized, double-blind comparison of carbamazepine (Tegretol) and barbital (Diemal). Acta Psychiatr Scand. 1984;69:398–408.CrossRefGoogle ScholarPubMed
49.Malcolm, R, Ballenger, JC, Sturgls, ET, Anton, R. Double-blind controlled trial comparing carbamazeplne to oxazepam treatment of alcohol withdrawal. Am J Psychiatry. 1989;146:617–621.Google ScholarPubMed
50.Ritola, E, Malinen, L. A double-blind comparison of carbamazepine and clomethiazole in the treatment of alcohol withdrawal syndrome. Acta Psychiatr Scand. 1981,64:254–259.CrossRefGoogle ScholarPubMed
51.Franz, M, Dlabal, H, Kunz, S, Ulferts, J, Gruppe, H, Gallhofer, B. Treatment of alcohol withdrawal: tiapride and carbamazepine versus clomethiazole. A pilot study. Eur Arch Psychiatry Clin Neurosci. 2001;251:185–192.CrossRefGoogle ScholarPubMed
52.Lucht, M, Kuehn, KU, Armbruster, J, et al.Alcohol withdrawal treatment in Intoxicated vs non-Intoxicated patients: a controlled open-label study with tiapride/car-bamazepine, clomethiazole and diazepam. Alcohol Alcohol. 2003;38:168–175.CrossRefGoogle Scholar
53.Soyka, M, Schmidt, P, Franz, M, et al.Treatment of alcohol withdrawal syndrome with a combination of tiapride/carbamazepine: results of a pooled analysis in 540 patients. Eur Arch Psychiatry Clin Neurosci. 2006;256:295–401.CrossRefGoogle ScholarPubMed
54.Soyka, M. F. S., Schmidt, P. Efficacy and safety of outpatient alcohol detoxification with a combination of tiapride/carbamazepine: additional evidence. Pharmacopsychiatry. 2006;39:30–34.CrossRefGoogle ScholarPubMed
55.Swantek, SS, Grossberg, GT, Neppe, VM, Doubek, WG, Martin, T, Bender, JE. The use of carbamazeplne to treat benzodiazepine withdrawal in a geriatric population. J Geriatr Psychiatry Neurol. 1991;4:106–109.CrossRefGoogle Scholar
56.Ries, PK, Roy-Byrne, PPWard, NG, Neppe, V, Cullison, S. Carbamazepine treatment for benzodiazepine withdrawal. Am J Psychiatry. 1989;146:536–537.Google ScholarPubMed
57.Klein, E, Uhde, T, Post, RM. Preliminary evidence of the utility of carbamazepine in alprazolam withdrawal. Am J Psychiatry. 1986;143:235–236.Google ScholarPubMed
58.Schweizer, E, Rickeis, K, Case, WG, Greenblat, DJ. Carbamazepine treatment In patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and outcome. Arch Gen Psychiatry. 1991;48:448–453.CrossRefGoogle ScholarPubMed
59.Klein, E, Colin, V, Stolk, J, Lenox, RH. Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazeplne. Am J Psychiatry. 1994;151:1760–1766.Google Scholar
60.Kaendler, SH, Volk, S, Pflug, B. Benzodiazepine withdrawal and carbamazepine. Nervenarzt. 1996;67:381–386.Google ScholarPubMed
61.Schik, G, Wedegaertner, FR, Liersch, J, Hoy, L, Emrich, HM, Schneider, U. Oxcarbazepine vs carbamazeplne in the treatment of alcohol withdrawal. Addict Biol. 2005;10:283–288.CrossRefGoogle Scholar
62.Croissant, B, Loeber, S, Diehl, A, et al.Oxcarbazepine in combination with Tiaprid in Inpatient alcohol-withdrawal-a RCT. Pharmacopsychiatry. 2009;42:175–181.CrossRefGoogle ScholarPubMed
63.Rustembegovlc, A, Sofie, E, Kroyer, G. A pilot study of Toplramate (Topamax) in the treatment of tonic-clonlc seizures of alcohol withdrawal syndromes. Med Arh. 2002:56:211–212.Google Scholar
64.Krupitsky, EM, Rudenko, AA, Burakov, AM, et al.Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res. 2007;31:604–611.CrossRefGoogle ScholarPubMed
65.Bonnet, U, Banger, M, Leweke, FM, Maschke, M, Kowalski, T, Gastpar, M. Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry. 1999;32:107–109.CrossRefGoogle ScholarPubMed
66.Bezikas, VPetrikis, RGamvrula, K, Sawidou, I, Karavatos, A. Treatment of alcohol withdrawal with gabapentin. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:197–199.CrossRefGoogle Scholar
67.Voris, J, Smith, NL, Rao, SM, Thome, DL, Flowers, QJ. Gabapentin for the treatment of ethanol withdrawal. Subst Abus. 2003;24:129–132.CrossRefGoogle ScholarPubMed
68.Mariani, JJ, Rosenthal, RN, Tross, S, Singh, RAnand, OP. A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal. Am J Addict. 2006;15:76–84.CrossRefGoogle ScholarPubMed
69.Bonnet, U, Banger, M, Leweke, FM, et al.Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-center trial. J Clin Pharmacol. 2003;23:14–19.Google ScholarPubMed
70.Malcolm, R, Myrick, LH, Veatch, LM, Boyle, E, Randall, PK. Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin. J Clin Sleep Med. 2007;3:24–32.Google ScholarPubMed
71.Karam-Hage, M, Brower, KJ. Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients. Psychiatry Clin Neurosci. 2003;57:542–544.CrossRefGoogle ScholarPubMed
72.Brower, KJ, Myra Kim, H, Strobbe, S, Karam-Hage, MA, Consens, RZucker, RA. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res. 2008;32:1429–1438.CrossRefGoogle ScholarPubMed
73.Bonnet, U, Specka, M, Leweke, FM, Nyhuls, P, Banger, M. Gabapentin's acute effect on mood profile--a controlled study on patients with alcohol withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:434–438.CrossRefGoogle Scholar
74.Lambie, DG, Johnson, RH, Vijayasenan, ME, Whiteside, EA. Sodium valproate in the treatment of the alcohol withdrawal syndrome. Aust N Z J Psychiatry. 1980;14:213–215.CrossRefGoogle ScholarPubMed
75.Reoux, JPSaxon, AJ, Malte, CA, Baer, JS, Sloan, KL. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res. 2001;25:1324–1329.Google ScholarPubMed
76.Myrick, H, Brady, KT, Malcolm, R. Divalproex in the treatment of alcohol withdrawal. Am J Drug Alcohol Abuse. 2000;26:155–160.CrossRefGoogle ScholarPubMed
77.Longo, LP, Campbell, T, Hubatch, S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis. 2002;21:55–64.CrossRefGoogle ScholarPubMed
78.Rosenthal, RN, Perkel, C, Singh, P. Anand, O, Miner, CR. A pilot open randomized trial of valproate and phenobarbital in the treatment of acute alcohol withdrawal. Am J Addict. 1998;7:189–197.CrossRefGoogle ScholarPubMed
79.Rickeis, K, Schweizer, E, Garcia, ERCase, G, DeMartinis, N, Greenblatt, D. Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology. 1999;141:1–5.CrossRefGoogle Scholar
80.Banger, M, Benkert, O, Röschke, J, et al.Nimodipine in acute alcohol withdrawal state. J Psychiatr Res. 1992:26:117–123.CrossRefGoogle ScholarPubMed
81.Altamura, AC, Regazzettl, MG, Porta, M. Nimodipine in human alcohol withdrawal syndrome--an open study. Eur Neuropsychopharmacol. 1990;1:37–40.CrossRefGoogle ScholarPubMed
82.Gatti, A, Munari, L, Perretti, A, Porta, M, Altamura, C, Ragazzetti, MG. Sequential nlmodipine-reduced glutathione treatment in alcoholic abstinence syndrome. Preliminary experience. Minerva Med. 1992;83:277–281.Google ScholarPubMed
83.Krupitskii, EM, Burakov, AM, Priputina, LS, et al.[The efficacy of calcium channel blockers In the treatment of affective disorders and pathologic drive for alcohol in patients with alcoholism in the remission period]. Zh Nevrol Psikhiatr Im S S Korsakova. 2004;104:50–53.Google ScholarPubMed
84.Polycarpou, A, Papanikolaou, Rloannidis, JPContopoulos-loannidis, DG. Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev. 2005;3:CD005064.CrossRefGoogle Scholar
85.Jasinski, DR, Nutti, JG, Haertzen, CA, Griffith, JD. Lithium: Effects on subjective functioning and morphine-Induced euphoria. Science. 1977;195:582–584.CrossRefGoogle ScholarPubMed
86.Bertschy, G, Bryois, C, Bondolfi, G, et al.The association carbamazepine-mianserin in opiate withdrawal: a double blind pilot study versus Clonidine. Pharmacological Research. 1997;35:451–456.CrossRefGoogle ScholarPubMed
87.Eichelbaum, M, von Unruh, GE, Somogyi, A. Application of stable labelled drugs in clinical pharmacokinetic investigations. Clin Pharmacokinet. 1982;7:490–507.CrossRefGoogle ScholarPubMed
88.Kumar, P, Jain, MK. Gabapentin in the management of pentazocine dependence: a potent analgesic-antlcraving agent. J Assoc Physicians India. 2003;51:673–676.Google ScholarPubMed
89.Martinez-Raga, J, Sabater, A, Perez-Galvez, B, Castellano, M, Cervera, G. Add-on gabapentin in the treatment of opiate withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:599–601.CrossRefGoogle ScholarPubMed
90.Freye, E, Levy, JV, Partecke, L. Use of gabapentin for attenuation of symptoms following rapid opiate detoxification (ROD)-correlation with neurophysiologlcal parameters. Neurophysiol Clin. 2004;34:81–89.CrossRefGoogle ScholarPubMed
91.Kheirabadi, GR, Ranjkesh, M, Maracy, MR, Salehi, M. Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients. Addiction. 2008;103:1495–1499.CrossRefGoogle ScholarPubMed
92.Ignatov, ID, Andreev, BV. [Role of opioid and adrenergic mechanisms in the analgesic action of GABA-positlve drugs]. Biull Eksp Biol Med. 1988;105:556–558.CrossRefGoogle ScholarPubMed
93.Tamayo, L, Contreras, E. A dual action of valproic acid upon morphine analgesia and morphine withdrawal. Pharmacology. 1983;26:297–302.CrossRefGoogle ScholarPubMed
94.Saxon, AJ, Whittaker, S, Hawker, CS. Valproic acid, unlike other anticonvulsants has no effect on methadone metabolism: two cases. J Clin Psychiatry. 1989;50:228–229.Google ScholarPubMed
95.Jiménez-Lerma, JM, Landabaso, M, Iraurgi, L, Calle, R, Sanz, J, Gutiérrez-Fraile, M. Nimodipine in opiate detoxification: a controlled trial. Addiction. 2002;97:819–824.CrossRefGoogle ScholarPubMed
96.Santillán, R, Hurlé, MA, Armijo, JA, de los Mozos, R, Flórez, J. Nimodipine-enhanced opiate analgesia in cancer patients requiring morphine dose escalation: a double-blind, placebo-controlled study. Pain. 1998;76:17–26.CrossRefGoogle ScholarPubMed
97.Rosen, Ml, Pearsall, HR, Kosten, TR. The effect of lamotrigine on naloxone-precipl-tated opiate withdrawal. Drug Alcohol Depend. 1998;52:173–176.CrossRefGoogle ScholarPubMed
98.Pani, PRAgus, A, Gessa, GL. Methadone as a mood stabilizer [Letter]. Heroin Addict Relat Clin Probl. 1999;1 (1):43–44.Google Scholar
99.Maremmani, I, Canoniero, S, Pacini, M. Methadone dose and retention in treatment of heroin addicts with Bipolar I Disorder comorbidity. Preliminary Results. Heroin Addict Belat Clin Probl. 2000;2:39–46.Google Scholar
100.Altamura, AC. Therapeutic attempts with lithium in young drug addicts. Acta Psychiatr Scand 1975;52:312–319.CrossRefGoogle ScholarPubMed
101.Merry, J, Reynolds, C, Bailey, J, Coppen, A. Prophylactic treatment of alcoholism by lithium carbonate. A controlled study. Lancet. 1976;1:481–482.CrossRefGoogle ScholarPubMed
102.Clark, DC, Fawcett, J. Does lithium carbonate therapy for alcoholism deter relapse drinking? Recent Dev Alcohol. 1989;7:315–328.CrossRefGoogle ScholarPubMed
103.Fawcett, J, Clark, DC, Aagesen, CA, et al.A double-blind, placebo-controlled trial of lithium carbonate therapy for alcoholism. Arch Gen Psychiatry. 1987;44:248–256.CrossRefGoogle ScholarPubMed
104.Fawcett, J, Clark, DC, Gibbons, RD, et al.Evaluation of lithium therapy for alcoholism. J Clin Psychiatry. 1984;45:494–499.Google ScholarPubMed
105.Pond, SM, Becker, CE, Vandervoort, R, Phillips, M, Bowler, RM, Peck, CC. An evaluation of the effects of lithium In the treatment of chronic alcoholism. I. Clinical results. Alcohol Clin Exp Res. 1981;5:247–251.CrossRefGoogle ScholarPubMed
106.Powell, BJ, Penick, EC, Liskow, Bl, Rice, AS, McKnelly, W. Lithium compliance in alcoholic males: a six month followup study. Addict Behav. 1986;11:135–140.CrossRefGoogle Scholar
107.Olbrich, R, Watzl, H, Volter, M, Siedow, H. Lithium in the treatment of chronic alcoholic patients with brain damage, a controlled study. Nervenarzt 1991;62:182–186.Google ScholarPubMed
108.Dorus, W, Ostrow, D, Anton, R, et al.Lithium treatment of depressed and nonde-pressed alcoholics. JAMA. 1989;262:1646–1652.CrossRefGoogle ScholarPubMed
109.de la Fuente, JR, Morse, RM, Niven, RG, Ilstrup, DM. A controlled study of lithium carbonate in the treatment of alcoholism. Mayo Clin Proc. 1989;64:177–180.CrossRefGoogle ScholarPubMed
110.Brady, KT, Sonne, SC, Malcolm, RJ, et al.Carbamazepine in the treatment of cocaine dependence: subtyping by affective disorder. Exp Clin Psychopharmacol. 2002;10:276–285.CrossRefGoogle ScholarPubMed
111.Salloum, IM, Cornelius, JR, Daley, DC, Kirisci, L, Himmelhoch, JM, Thase, ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2005;62:37–45.CrossRefGoogle ScholarPubMed
112.Johnson, BA, Ait-Daoud, N, Bowden, CL, et al.Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677–1685.CrossRefGoogle ScholarPubMed
113.Fernandez Miranda, JJ, Marina Gonzàlez, PA, Montes Pérez, M, et al.Topiramate as add-on therapy in non-respondent alcohol dependant patients: a 12 month follow up study. Acta Esp Psiquiatr. 2007;35:236–242.Google ScholarPubMed
114.Croissant, B, Diehl, A, Klein, O, et al.A pilot study of oxcarbazepine versus acampro-sate in alcohol-dependent patients. Alcohol Clin Exp Res. 2006;30:630–635.CrossRefGoogle ScholarPubMed
115.Martinotti, G, Di Nicola, M, Romanelli, R, et al.High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients. Hum Psychopharmacol. 2007;22:149–156.CrossRefGoogle ScholarPubMed
116.Myrick, H, Anton, R, Voronin, K, Wang, W, Henderson, S. A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcohol Clin Exp Res. 2007;31:221–227.CrossRefGoogle Scholar
117.Martinotti, G, Nicola, MD, Reina, D, et al.Alcohol protracted withdrawal syndrome: the role of anhedonia. Subst Use Misuse. 2008;43:271–284.CrossRefGoogle ScholarPubMed
118.Nunes, EW, McGrath, PJ, Wager, S, Quitkin, FM. Lithium treatment for cocaine abusers with bipolar spectrum disorders. Am J Psychiatry. 1990;147:655–657.Google ScholarPubMed
119.Gawin, FH, Ellinwood, EH. Cocaine dependence. Ann Rev Med. 1989;40:149–161.CrossRefGoogle ScholarPubMed
120.Gawin, FH, Kleber, HD. Cocaine abuse treatment: open pilot trial with desipramine and lithium carbonate. Arch Gen Psychiatry. 1984;41:903–909.CrossRefGoogle ScholarPubMed
121.Campbell, JL, Thomas, HM, Gabrielli, W, Liskow, Bl, Powell, BJ. Impact of desipramine or carbamazepine on patient retention in outpatient cocaine treatment: preliminary findings. J Addict Dis. 1994;13:191–199.CrossRefGoogle ScholarPubMed
122.Halikas, JA, Center, BA, Pearson, VL, Carlson, GA, Crea, F. A pilot, open clinical study of depakote in the treatment of cocaine abuse. Human Psychopharmacology. 2001;16:257–264.CrossRefGoogle ScholarPubMed
123.Myrick, H, Henderson, S, Brady, K, Malcom, R, Measom, M. Divalproex loading in the treatment of cocaine dependence. J Psychoactive Drugs. 2001;33:283–287.CrossRefGoogle ScholarPubMed
124.Reid, MS, Casadonte, P, Baker, S, et al.A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitlne for the treatment of cocaine dependence. Addiction. 2005;100(S1):43–57.CrossRefGoogle ScholarPubMed
125.Brown, ES, Nejtek, VA, Perantle, DC, Orsulak, PJ, Bobadilla, L. Lamotrigine in patients with bipolar disorder and cocaine dependence. J Clin Psychiatry. 2003;64:197–201.CrossRefGoogle ScholarPubMed
126.Brown, ES, Perantie, DC, Dhanani, N, Beard, L, Orsulak, P, Rush, AJ. Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study. Addiction. 2006;93:219–222.Google ScholarPubMed
127.Berger, SP, Winhusen, TM, Somoza, EC, et al.A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. Addiction. 2005;100(S1):58–67.CrossRefGoogle ScholarPubMed
128.Margolin, A, Avants, SK, DePhilippis, D, Kosten, TR. A preliminary Investigation of lamotrigine for cocaine abuse in HIV-seroposltive patients. Am J Drug Alcohol Abuse. 1998;24:85–101.CrossRefGoogle ScholarPubMed
129.Perretta, RAkiskal, HS, Nisita, C, et al.The high prevalence of bipolar II and associated cyclothymic and hyperthymic temperaments in HIV-patients. J Affect Disord. 1998;50:215–224.CrossRefGoogle ScholarPubMed
130.Raby, W, Coomaraswamy, S. Gabapentin reduces cocaine use among addicts from a community clinic sample. J Clin Psychiatry. 2004;65:84–86.CrossRefGoogle ScholarPubMed
131.Myrick, H, Henderson, S, Brady, K, Malcolm, R. Gabapentin in the treatment of cocaine dependence: a case series. J Clin Psychiatry. 2001;62:19–23.CrossRefGoogle ScholarPubMed
132.Haney, M, Hart, C, Collins, ED, Foltin, RW. Smoked cocaine discrimination in humans: effects of gabapentin. Drug Alcohol Depend. 2005;80:53–61.CrossRefGoogle ScholarPubMed
133.Hart, CL, Haney, M, Vosburg, SK, Rubin, E, Foltin, RW. Gabapentin does not reduce smoked cocaine self-administration: employment of a novel self-administration procedure. Behav Pharmacol. 2007;18:71–75.CrossRefGoogle Scholar
134.Gonzalez, G, Desaj, R, Sofuoglu, M, et al.Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend. 2007;87:1–9.CrossRefGoogle ScholarPubMed
135.Hart, CL, Haney, M, Collins, ED, Rubin, E, Foltin, RW. Smoked cocaine self-admlnls-tration by humans is not reduced by large gabapentin maintenance doses. Drug Alcohol Depend. 2007;86:274–277.CrossRefGoogle Scholar
136.Sharpe, LG, Jaffe, JH, Katz, JL. Carbamazepine produces nonspecific effects on cocaine self-administration in rats. Life Sci. 1992;51:13–18.CrossRefGoogle ScholarPubMed
137.Carroll, ME, Lac, ST, Asencio, M, Halikas, JA, Kragh, R. Effects of carbamazeplne on self-administration of intravenously delivered cocaine in rats. Pharmacol Biochem Behav. 1990;37:551–556.CrossRefGoogle ScholarPubMed
138.Baptista, T, Weiss, SR, Post, RM. Carbamazepine attenuates cocaine-induced increases in dopamine in the nucleus accumbens: an in vivo dialysis study. Eur J Pharmacol. 1993;236:39–42.CrossRefGoogle ScholarPubMed
139.Hatsukami, D, Keenan, R, Halikas, J, Pentel, PR, Brauer, LH. Effects of carbamazeplne on acute responses to smoked cocaine-base in human cocaine users. Psychopharmacology. 1991;104:120–124.CrossRefGoogle ScholarPubMed
140.Halikas, JA, Crosby, RD, Pearson, VL, Graves, NM. A randomized double-blind study of carbamazepine in the treatment of cocaine abuse. Clin Pharmacol Ther. 1997;62:89–105.CrossRefGoogle ScholarPubMed
141.Halikas, JA, Crosby, RD, Carlson, GA, Crea, RGraves, NM, Bowers, LD. Cocaine reduction in unmotivated crack users using carbamazepine versus placebo in a short-term, double-blind crossover design. Clin Pharmacol Ther. 1991;50:81–95.CrossRefGoogle Scholar
142.Montoya, ID, Levin, FR, Fudala, PJ, et al.Double-blind comparison of carbamazepine and placebo for treatment of cocaine dependence. Drug Alcohol Depend. 1995;38:213–219.CrossRefGoogle ScholarPubMed
143.Kranzler, HR, Bauer, LO, Hersh, D, Klinghoffer, V. Carbamazepine treatment of cocaine dependence: a placebo-controlled trial. Drug Alcohol Depend. 1995;38:203–211.CrossRefGoogle ScholarPubMed
144.Lima, AR, Lima, MS, Soares, BG, Farrell, M. Carbamazepine for cocaine dependence. Cochrane Database Syst Rev. 2002;2:CD002023.CrossRefGoogle Scholar
145.Kuhn, KL, Halikas, JA, Kemp, KD. Carbamazeplne treatment of cocaine dependence in methadone maintenance patients with dual opiate-cocaine addiction. NIDA Res Monogr. 1989;95:316–317.Google ScholarPubMed
146.Halikas, JA, Kuhn, KL, Crea, FS, Carlson, GA, Crosby, R. Treatment of crack cocaine use with carbamazepine. Am J Drug Alcohol Abuse. 1992;18:45–56.CrossRefGoogle ScholarPubMed
147.Llopis Llacer, JJ, Castillo Aguilella, A. [Efficacy of oxcarbazepine treatment in patients diagnosed with cocaine abuse/dependence]. Adicciones. 2008;20:263–270.Google ScholarPubMed
148.Minozzi, S, Amato, L, Davoli, M, et al.Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev. 2008;2:CD006754.CrossRefGoogle Scholar
149.Nagel, K, Adler, L, Bell, J, Nagamoto, H, Freedman, R. Lithium carbonate and mood disorder in recently detoxified alcoholics: a double-blind, placebo-controlled pilot study. Alcohol Clin Exp Res. 1991; 15:978–981.CrossRefGoogle ScholarPubMed
150.Weiss, RD, Mirin, SM, Tricyclic antidepressants in the treatment of alcoholism and drug abuse. J Clin Psychiatry. 1989;50(Suppl:4-9); discussion 9–11.Google ScholarPubMed
151.Albanese, MJ, Clodfelter, RCJ, Khantzlan, EJ. Divalproex sodium in substance abusers with mood disorder. J Clin Psychiatry. 2000;61:916–921.CrossRefGoogle ScholarPubMed
152.Brady, KT, Sonne, SC, Anton, R, Ballenger, JC. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry. 1995;56:118–121.Google ScholarPubMed
153.Hertzman, M. Divalproex sodium to treat concomitant substance abuse and mood disorders. Subst Abuse Treat. 2000;18:371–372.CrossRefGoogle ScholarPubMed
154.Roberts, JM, Malcolm, R, Santos, AB. Treatment of panic disorder and comorbid substance abuse with divalproex sodium. Am J Psychiatry. 1994;151:1521.Google ScholarPubMed
155.Campbell, J, Nickel, EJ, Penick, EC, et al.Comparison of desipramine or carbamazepine to placebo for crack cocaine-dependent patients. Am J Addict 2003;12:122–136.Google ScholarPubMed
156.Ballenger, JC, Post, RM. Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses. Psychopharmacol Bull. 1984;20:572–584.Google ScholarPubMed
157.Hernandez-Avila, CA, Ortega-Soto, HA, Jasso, A, Hasfura-Buenaga, CA, Kranzler, HR. Treatment of inhalant-induced psychotic disorder with carmabazepine verus haloperidol. Psychiatr Serv. 1998;49:812–815.CrossRefGoogle Scholar
158.Camacho, A, Akiskal, HS. Proposal for a bipolar-stimulant spectrum: temperament, diagnostic validation and therapeutic outcomes with mood stabilizers. J Affect Disord. 2005;85:217–230.CrossRefGoogle ScholarPubMed
159.Keck, PEJ, McElroy, SL, Friedman, LM. Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. J Clin Pharmacol. 1992:(1 suppl):36s–41s.Google ScholarPubMed
160.Skinstad, AH, Swain, A. Comorbidity in a clinical sample of substance abusers. Am J Drug Alcohol Abuse. 2001;27(1):45–64.CrossRefGoogle Scholar